A new FDA study found patients taking a high dose of Vioxx, a popular anti-arthritis medicine, were three times more likely to have a heart attack. As a result, Merck & Co. is pulling the arthritis drug from the market.
Our firm has 58 cases filed against Merck in various states, including Alabama, New Jersey, Virginia, Mississippi, Florida and Georgia.
“It’s a shame that it has taken Merck this long to acknowledge what we have been saying for years: Vioxx is a dangerous drug,” said Andy Birchfield of Beasley, Allen, Crow, Methvin, Portis & Miles.
The withdrawal of Vioxx is a good move but much too late. It’s hard to accept that drug companies put bad drugs on the market for the sake of profit.
Two weeks ago the FDA approved the use of Vioxx for children. What was the FDA thinking? Changes must be made to ensure that the FDA protects the public, not the profits of pharmaceutical companies.
Andy Birchfield handles Vioxx litigation for the firm of Beasley, Allen, Crow, Methvin, Portis & Miles P.C.